ArticleRenal failure2026
External validation and comparative performance of four risk scores for acute kidney injury in critically ill adults.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral parsimonious scores predict acute kidney injury (AKI), but their comparative performance in critically ill adults is uncertain. We hypothesized that the ICU-derived UCSD-Mayo score would show higher discrimination than three scores developed in broader acute-care populations.
methodsThis single-center retrospective validation study included 1,723 emergency ICU patients admitted from 2014 to 2021. We compared the UCSD-Mayo, AKI-RiSc, Bell, and APS scores for in-hospital AKI, AKI within 7 days, and stages 2 and 3 AKI. Analyses included AUROC with paired DeLong comparisons, cross-validated local recalibration, calibration plots, IDI, categorical NRI at the event rate, decision-curve analysis, and prespecified sensitivity analyses.
resultsIn-hospital AKI occurred in 406 patients (23.6%), 281 (16.3%) developed AKI within 7 days, and 169 (9.8%) developed stages 2 and 3 AKI. UCSD-Mayo had the highest observed AUROC for in-hospital AKI (0.713, 95%CI 0.685-0.740), 7-day AKI (0.690, 0.658-0.723), and stages 2 and 3 AKI (0.706, 0.665-0.746). Its 7-day AUROC did not differ significantly from AKI-RiSc (difference 0.029, 95%CI -0.006 to 0.064;
conclusionsIn this single-center Chinese emergency ICU cohort, UCSD-Mayo showed the highest observed discrimination, but improvements were modest and were not uniform across all outcomes, metrics, or decision thresholds. These scores may support risk awareness and monitoring but should not be used as stand-alone treatment rules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.